Teladoc Health, Inc. (TDOC) stock
Close on Nov 17, 2026Market cap $1.55BP/E –Yield –
Earnings
Teladoc Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Teladoc Health's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 24, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 28, 2026after the close | $605.10M | -3.4% | -$0.15 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 29, 2026after the close | $606.90M | -4.0% | -$0.21 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 29, 2026after the close | $613.80M | -2.5% | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026after the close | $642.30M | +0.3% | -$0.14 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 23, 2025after the close | $626.40M | -2.2% | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 29, 2025after the close | $631.90M | -1.6% | -$0.19 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 30, 2025after the close | $629.40M | – | -$0.53 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 26, 2025after the close | $640.50M | -3.0% | -$0.28 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 30, 2024after the close | $640.50M | -3.0% | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 31, 2024after the close | $642.40M | -1.5% | -$4.92 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 5, 2024after the close | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 20, 2024after the close | $660.50M | +3.6% | -$0.17 | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 24, 2023after the close | $660.20M | +8.0% | -$0.35 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 25, 2023after the close | $652.40M | +10.1% | -$0.40 | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 26, 2023after the close | $629.20M | +11.3% | -$0.42 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 22, 2023after the close | $637.70M | +15.1% | -$23.49 | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 26, 2022after the close | $611.40M | +17.1% | -$0.45 | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 27, 2022after the close | $592.40M | – | -$19.22 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 27, 2022after the close | $565.40M | – | -$41.58 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 22, 2022after the close | $554.20M | – | -$0.07 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 27, 2021after the close | $522.00M | – | -$0.53 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 27, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 28, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 24, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 28, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Teladoc Health's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| RevenueGAAP | Q4 FY2026 | $569.00M – $615.00M | – | New | Oct 28, 2026 |
| Adjusted EBITDAnon-GAAP | Q4 FY2026 | $74.00M – $100.00M | – | New | Oct 28, 2026 |
| Net loss per shareGAAP | Q4 FY2026 | -$0.23 – -$0.03 | – | New | Oct 28, 2026 |
| BetterHelp Adjusted EBITDA marginnon-GAAP | Q4 FY2026 | 9.2% – 15.1% | – | Lowered | Oct 28, 2026 |
| BetterHelp Revenue growth percentage (year-over-year) | Q4 FY2026 | -31.5% – -18.5% | – | Lowered | Oct 28, 2026 |
| Integrated Care Adjusted EBITDA marginnon-GAAP | Q4 FY2026 | 14.5% – 16.8% | – | New | Oct 28, 2026 |
| Integrated Care Revenue growth percentage (year-over-year) | Q4 FY2026 | 0% – +3.8% | – | New | Oct 28, 2026 |
| U.S. Integrated Care Members (2) | Q4 FY2026 | 99.5 – 100.5 | – | New | Oct 28, 2026 |
| Integrated Care Revenue growth percentage (year-over-year) | FY2026 | +0.8% – +2.4% | +0.4% – +3.9% | Raised | Jul 29, 2026 |
| RevenueGAAP | FY2026 | $2.40B – $2.44B | – | New | Oct 28, 2026 |
| Revenue | FY2026 | $2.36B – $2.45B | $2.47B – $2.59B | Lowered | Jul 29, 2026 |
| Integrated Care Adjusted EBITDA marginnon-GAAP | FY2026 | 15.1% – 16.1% | – | New | Feb 25, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $277.00M – $303.00M | – | New | Oct 28, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $271.00M – $303.00M | $266.00M – $308.00M | Narrowed | Jul 29, 2026 |
| Net loss per shareGAAP | FY2026 | -$0.95 – -$0.75 | – | New | Oct 28, 2026 |
| Net loss per shareGAAP | FY2026 | -$1.00 – -$0.75 | -$1.10 – -$0.70 | Narrowed | Jul 29, 2026 |
| Free Cash Flownon-GAAP | FY2026 | $135.00M – $165.00M | – | New | Oct 28, 2026 |
| Free Cash Flownon-GAAP | FY2026 | $130.00M – $170.00M | $130.00M – $170.00M | Reaffirmed | Jul 29, 2026 |
| BetterHelp Adjusted EBITDA marginnon-GAAP | FY2026 | 2.7% – 4.3% | – | Lowered | Oct 28, 2026 |
| BetterHelp Adjusted EBITDA marginnon-GAAP | FY2026 | 3% – 4.6% | – | Lowered | Jul 29, 2026 |
| BetterHelp Revenue growth percentage (year-over-year) | FY2026 | -16.1% – -12.9% | – | Lowered | Oct 28, 2026 |
| Integrated Care Adjusted EBITDA marginnon-GAAP | FY2026 | 16% – 16.6% | – | New | Oct 28, 2026 |
| Integrated Care Adjusted EBITDA marginnon-GAAP | FY2026 | 15.6% – 16.4% | – | New | Jul 29, 2026 |
| Integrated Care Revenue growth percentage (year-over-year) | FY2026 | +1.1% – +2.1% | – | New | Oct 28, 2026 |
| U.S. Integrated Care Members | FY2026 | 98.5 – 100.5 | 97 – 100 | Raised | Jul 29, 2026 |
| U.S. Integrated Care Members (2) | FY2026 | 99.5 – 100.5 | – | New | Oct 28, 2026 |
Guidance vs results
The last range Teladoc Health gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | EPS (GAAP) | -$0.30 – -$0.20 | -$0.15 | Above range |
| Q3 FY2026 | Revenue | $569.00M – $609.00M | $605.10M | Within range |
| Q3 FY2026 | Revenue growth | 0% – +3% | -3.4% | Below range |
| Q1 FY2026 | Revenue | $598.00M – $620.00M | $613.80M | Within range |
| Q1 FY2026 | Revenue growth | -1.2% – +2% | -2.48% | Below range |
| Q3 FY2025 | Revenue | $614.00M – $636.00M | $626.40M | Within range |
| Q2 FY2025 | EPS (GAAP) | -$0.40 – -$0.20 | -$0.19 | Above range |
| Q2 FY2025 | Revenue | $614.00M – $633.00M | $631.90M | Within range |
| Q1 FY2025 | EPS (GAAP) | -$0.40 – -$0.15 | -$0.53 | Below range |
| Q1 FY2025 | Revenue | $608.00M – $629.00M | $629.40M | Above range |
| Q3 FY2024 | Revenue growth | -1% – +2% | -2.98% | Below range |
| Q4 FY2023 | EPS (GAAP) | -$0.33 – -$0.23 | -$0.17 | Above range |
| Q4 FY2023 | Revenue | $658.00M – $683.00M | $660.50M | Within range |
| Q3 FY2023 | EPS (GAAP) | -$0.50 – -$0.40 | -$0.35 | Above range |
| Q3 FY2023 | Revenue | $650.00M – $675.00M | $660.20M | Within range |
| Q2 FY2023 | EPS (GAAP) | -$0.55 – -$0.45 | -$0.40 | Above range |
| Q2 FY2023 | Revenue | $635.00M – $660.00M | $652.40M | Within range |
| Q1 FY2023 | EPS (GAAP) | -$0.55 – -$0.45 | -$0.42 | Above range |
| Q1 FY2023 | Revenue | $610.00M – $625.00M | $629.20M | Above range |
| Q4 FY2022 | EPS (GAAP) | -$0.40 – -$0.10 | -$23.49 | Below range |
| Q4 FY2022 | Revenue | $625.00M – $640.00M | $637.70M | Within range |
| Q3 FY2022 | EPS (GAAP) | -$0.85 – -$0.60 | -$0.45 | Above range |
| Q3 FY2022 | Revenue | $600.00M – $620.00M | $611.40M | Within range |
| Q2 FY2022 | EPS (GAAP) | -$0.72 – -$0.60 | -$19.22 | Below range |
| Q2 FY2022 | Revenue | $580.00M – $600.00M | $592.40M | Within range |
| Q1 FY2022 | EPS (GAAP) | -$0.60 – -$0.50 | -$41.58 | Below range |
| Q1 FY2022 | Revenue | $565.00M – $571.00M | $565.40M | Within range |
| Q4 FY2021 | EPS (GAAP) | -$0.73 – -$0.53 | -$0.07 | Above range |
| Q4 FY2021 | Revenue | $536.00M – $546.00M | $554.20M | Above range |
Guidance history
Every forecast Teladoc Health put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 28, 2026 | Adjusted EBITDA | Q4 FY2026 | $74.00M – $100.00M | New |
| Oct 28, 2026 | Adjusted EBITDA | FY2026 | $277.00M – $303.00M | New |
| Oct 28, 2026 | Net loss per share | Q4 FY2026 | -$0.23 – -$0.03 | New |
| Oct 28, 2026 | Net loss per share | FY2026 | -$0.95 – -$0.75 | New |
| Oct 28, 2026 | Free Cash Flow | FY2026 | $135.00M – $165.00M | New |
| Oct 28, 2026 | U.S. Integrated Care Members (2) | Q4 FY2026 | 99.5 – 100.5 | New |
| Oct 28, 2026 | Integrated Care Adjusted EBITDA margin | Q4 FY2026 | 14.5% – 16.8% | New |
| Oct 28, 2026 | BetterHelp Adjusted EBITDA margin | Q4 FY2026 | 9.2% – 15.1% | Lowered |
| Oct 28, 2026 | Integrated Care Revenue growth percentage (year-over-year) | Q4 FY2026 | 0% – +3.8% | New |
| Oct 28, 2026 | BetterHelp Revenue growth percentage (year-over-year) | Q4 FY2026 | -31.5% – -18.5% | Lowered |
| Oct 28, 2026 | U.S. Integrated Care Members (2) | FY2026 | 99.5 – 100.5 | New |
| Oct 28, 2026 | Integrated Care Adjusted EBITDA margin | FY2026 | 16% – 16.6% | New |
| Oct 28, 2026 | BetterHelp Adjusted EBITDA margin | FY2026 | 2.7% – 4.3% | Lowered |
| Oct 28, 2026 | Integrated Care Revenue growth percentage (year-over-year) | FY2026 | +1.1% – +2.1% | New |
| Oct 28, 2026 | BetterHelp Revenue growth percentage (year-over-year) | FY2026 | -16.1% – -12.9% | Lowered |
| Oct 28, 2026 | Revenue | Q4 FY2026 | $569.00M – $615.00M | New |
| Oct 28, 2026 | Revenue | FY2026 | $2.40B – $2.44B | New |
| Jul 29, 2026 | Adjusted EBITDA | FY2026 | $271.00M – $303.00M | Narrowed |
| Jul 29, 2026 | Adjusted EBITDA | Q3 FY2026 | $62.00M – $74.00M | New |
| Jul 29, 2026 | Net loss per share | FY2026 | -$1.00 – -$0.75 | Narrowed |
| Jul 29, 2026 | Net loss per share | Q3 FY2026 | -$0.30 – -$0.20 | New |
| Jul 29, 2026 | Free Cash Flow | FY2026 | $130.00M – $170.00M | Reaffirmed |
| Jul 29, 2026 | U.S. Integrated Care Members | FY2026 | 98.5 – 100.5 | Raised |
| Jul 29, 2026 | Integrated Care Adjusted EBITDA margin | FY2026 | 15.6% – 16.4% | New |
| Jul 29, 2026 | BetterHelp Adjusted EBITDA margin | FY2026 | 3% – 4.6% | Lowered |
| Jul 29, 2026 | U.S. Integrated Care Members | Q3 FY2026 | 99 – 100.5 | New |
| Jul 29, 2026 | Integrated Care Adjusted EBITDA margin | Q3 FY2026 | 15.7% – 17.2% | New |
| Jul 29, 2026 | BetterHelp Adjusted EBITDA margin | Q3 FY2026 | 0.5% – 2.5% | Lowered |
| Jul 29, 2026 | Integrated Care Revenue growth percentage (year-over-year) | FY2026 | +0.8% – +2.4% | Raised |
| Jul 29, 2026 | BetterHelp Revenue growth percentage (year-over-year) | FY2026 | -19% – -12.7% | Lowered |
| Jul 29, 2026 | Revenue | FY2026 | $2.36B – $2.45B | Lowered |
| Jul 29, 2026 | Integrated Care Revenue growth percentage (year-over-year) | Q3 FY2026 | 0% – +3% | New |
| Jul 29, 2026 | BetterHelp Revenue growth percentage (year-over-year) | Q3 FY2026 | -24.2% – -12.3% | Lowered |
| Jul 29, 2026 | Revenue | Q3 FY2026 | $569.00M – $609.00M | New |
| Feb 25, 2026 | Adjusted EBITDA | FY2026 | $266.00M – $308.00M | New |
| Feb 25, 2026 | Adjusted EBITDA | Q1 FY2026 | $50.00M – $62.00M | New |
| Feb 25, 2026 | Net loss per share | FY2026 | -$1.10 – -$0.70 | New |
| Feb 25, 2026 | Net loss per share | Q1 FY2026 | -$0.45 – -$0.35 | New |
| Feb 25, 2026 | Free Cash Flow | FY2026 | $130.00M – $170.00M | New |
| Feb 25, 2026 | Integrated Care Adjusted EBITDA margin | FY2026 | 15.1% – 16.1% | New |
| Feb 25, 2026 | BetterHelp Adjusted EBITDA margin | FY2026 | 3% – 4.6% | Lowered |
| Feb 25, 2026 | Integrated Care Adjusted EBITDA margin | Q1 FY2026 | 12.5% – 14% | New |
| Feb 25, 2026 | BetterHelp Adjusted EBITDA margin | Q1 FY2026 | 0.75% – 2.75% | Lowered |
| Feb 25, 2026 | U.S. Integrated Care Members | FY2026 | 97 – 100 | New |
| Feb 25, 2026 | U.S. Integrated Care Members | Q1 FY2026 | 99 – 100 | New |
| Feb 25, 2026 | Integrated Care Revenue growth percentage (year-over-year) | FY2026 | +0.4% – +3.9% | New |
| Feb 25, 2026 | BetterHelp Revenue growth percentage (year-over-year) | FY2026 | -7% – -0.5% | Lowered |
| Feb 25, 2026 | Revenue | FY2026 | $2.47B – $2.59B | New |
| Feb 25, 2026 | Integrated Care Revenue growth percentage (year-over-year) | Q1 FY2026 | -1.2% – +2% | New |
| Feb 25, 2026 | BetterHelp Revenue growth percentage (year-over-year) | Q1 FY2026 | -11.25% – -7% | Lowered |
| Feb 25, 2026 | Revenue | Q1 FY2026 | $598.00M – $620.00M | New |
| Jul 29, 2025 | Capex | FY2025 | -$139.00M – -$129.00M | New |
| Jul 29, 2025 | Adjusted EBITDA | Q3 FY2025 | $56.00M – $70.00M | New |
| Jul 29, 2025 | Adjusted EBITDA | FY2025 | $263.00M – $294.00M | Lowered |
| Jul 29, 2025 | Net loss per share | Q3 FY2025 | -$0.35 – -$0.20 | New |
| Jul 29, 2025 | Net loss per share | FY2025 | -$1.35 – -$1.00 | Narrowed |
| Jul 29, 2025 | Free Cash Flow | FY2025 | $170.00M – $200.00M | Reaffirmed |
| Jul 29, 2025 | U.S. Integrated Care Members (2) | Q3 FY2025 | 101.5 – 102.5 | New |
| Jul 29, 2025 | Integrated Care Adjusted EBITDA margin | Q3 FY2025 | 14% – 15.5% | New |
| Jul 29, 2025 | BetterHelp Adjusted EBITDA margin | Q3 FY2025 | 1% – 3.75% | Lowered |
| Jul 29, 2025 | Integrated Care Revenue growth percentage (year-over-year) | Q3 FY2025 | -0.5% – +2.25% | New |
| Jul 29, 2025 | BetterHelp Revenue growth percentage (year-over-year) | Q3 FY2025 | -9.75% – -5% | Lowered |
| Jul 29, 2025 | Net income (loss) | Q3 FY2025 | -$62.00M – -$35.00M | New |
| Jul 29, 2025 | U.S. Integrated Care Members (2) | FY2025 | 101 – 103 | Reaffirmed |
| Jul 29, 2025 | Integrated Care Adjusted EBITDA margin | FY2025 | 14.5% – 15.25% | Raised |
| Jul 29, 2025 | BetterHelp Adjusted EBITDA margin | FY2025 | 4% – 5.5% | Lowered |
| Jul 29, 2025 | Integrated Care Revenue growth percentage (year-over-year) | FY2025 | +1.75% – +3.25% | Raised |
| Jul 29, 2025 | BetterHelp Revenue growth percentage (year-over-year) | FY2025 | -9.2% – -6.8% | Lowered |
| Jul 29, 2025 | Net income (loss) | FY2025 | -$238.00M – -$176.00M | Lowered |
| Jul 29, 2025 | Net cash provided by operating activities | FY2025 | $309.00M – $329.00M | Raised |
| Jul 29, 2025 | Revenue | Q3 FY2025 | $614.00M – $636.00M | New |
| Jul 29, 2025 | Revenue | FY2025 | $2.50B – $2.55B | Narrowed |
| Apr 30, 2025 | Capex | FY2025 | -$139.00M – -$129.00M | New |
| Apr 30, 2025 | Adjusted EBITDA | Q2 FY2025 | $56.00M – $70.00M | New |
| Apr 30, 2025 | Adjusted EBITDA | FY2025 | $263.00M – $304.00M | Lowered |
| Apr 30, 2025 | Net loss per share | Q2 FY2025 | -$0.40 – -$0.20 | New |
| Apr 30, 2025 | Net loss per share | FY2025 | -$1.40 – -$0.90 | Lowered |
| Apr 30, 2025 | Free Cash Flow | FY2025 | $170.00M – $200.00M | Lowered |
| Apr 30, 2025 | Integrated Care Adjusted EBITDA margin | Q2 FY2025 | 13.25% – 14.75% | New |
| Apr 30, 2025 | BetterHelp Adjusted EBITDA margin | Q2 FY2025 | 2.5% – 5.25% | Lowered |
| Apr 30, 2025 | Integrated Care Adjusted EBITDA margin | FY2025 | 14.3% – 15.3% | New |
| Apr 30, 2025 | BetterHelp Adjusted EBITDA margin | FY2025 | 4.75% – 6.25% | Lowered |
| Apr 30, 2025 | U.S. Integrated Care Members | Q2 FY2025 | 101.5 – 102.5 | New |
| Apr 30, 2025 | Integrated Care Revenue growth percentage (year-over-year) | Q2 FY2025 | +0.25% – +2.75% | New |
| Apr 30, 2025 | BetterHelp Revenue growth percentage (year-over-year) | Q2 FY2025 | -11.25% – -7.5% | Lowered |
| Apr 30, 2025 | Net income (loss) | Q2 FY2025 | -$70.00M – -$35.00M | New |
| Apr 30, 2025 | U.S. Integrated Care Members | FY2025 | 101 – 103 | Reaffirmed |
| Apr 30, 2025 | Integrated Care Revenue growth percentage (year-over-year) | FY2025 | 0% – +3% | Raised |
| Apr 30, 2025 | BetterHelp Revenue growth percentage (year-over-year) | FY2025 | -9.75% – -3.75% | Lowered |
| Apr 30, 2025 | Net income (loss) | FY2025 | -$247.00M – -$159.00M | New |
| Apr 30, 2025 | Net cash provided by operating activities | FY2025 | $309.00M – $329.00M | Raised |
| Apr 30, 2025 | Revenue | Q2 FY2025 | $614.00M – $633.00M | New |
| Apr 30, 2025 | Revenue | FY2025 | $2.47B – $2.58B | Reaffirmed |
| Feb 26, 2025 | Adjusted EBITDA | Q1 FY2025 | $47.00M – $59.00M | New |
| Feb 26, 2025 | Adjusted EBITDA | FY2025 | $278.00M – $319.00M | New |
| Feb 26, 2025 | Net loss per share | Q1 FY2025 | -$0.40 – -$0.15 | New |
| Feb 26, 2025 | Net loss per share | FY2025 | -$1.10 – -$0.50 | New |
| Feb 26, 2025 | Free Cash Flow | FY2025 | $190.00M – $220.00M | New |
| Feb 26, 2025 | U.S. Integrated Care Members (2) | Q1 FY2025 | 101 – 102 | New |
| Feb 26, 2025 | Integrated Care Adjusted EBITDA margin | Q1 FY2025 | 11.25% – 12.75% | New |
| Feb 26, 2025 | BetterHelp Adjusted EBITDA margin | Q1 FY2025 | 2% – 4.25% | Lowered |
| Feb 26, 2025 | Integrated Care Revenue growth percentage (year-over-year) | Q1 FY2025 | -0.5% – +2% | New |
| Feb 26, 2025 | BetterHelp Revenue growth percentage (year-over-year) | Q1 FY2025 | -13.5% – -9% | Lowered |
| Feb 26, 2025 | U.S. Integrated Care Members (2) | FY2025 | 101 – 103 | New |
| Feb 26, 2025 | Integrated Care Adjusted EBITDA margin | FY2025 | 14.3% – 15.3% | New |
| Feb 26, 2025 | BetterHelp Adjusted EBITDA margin | FY2025 | 6.25% – 7.75% | Lowered |
| Feb 26, 2025 | Integrated Care Revenue growth percentage (year-over-year) | FY2025 | 0% – +3% | New |
| Feb 26, 2025 | BetterHelp Revenue growth percentage (year-over-year) | FY2025 | -9.75% – -3.75% | Lowered |
| Feb 26, 2025 | Revenue | Q1 FY2025 | $608.00M – $629.00M | New |
| Feb 26, 2025 | Revenue | FY2025 | $2.47B – $2.58B | New |
| Jul 31, 2024 | Adjusted EBITDA margin | Q3 FY2024 | 14.5% – 16% | New |
| Jul 31, 2024 | Adjusted EBITDA margin expansion (year-over-year) | FY2024 | 150 – 200 | New |
| Jul 31, 2024 | U.S. Integrated Care Members (2) | Q3 FY2024 | 92.5 – 93.5 | New |
| Jul 31, 2024 | U.S. Integrated Care Members (2) | FY2024 | 92.5 – 94 | Raised |
| Jul 31, 2024 | Revenue growth percentage (year-over-year) | Q3 FY2024 | -1% – +2% | New |
| Feb 20, 2024 | Adjusted EBITDA | Q1 FY2024 | $52.00M – $62.00M | New |
| Feb 20, 2024 | Adjusted EBITDA | FY2024 | $350.00M – $390.00M | New |
| Feb 20, 2024 | Net loss per share | Q1 FY2024 | -$0.55 – -$0.45 | New |
| Feb 20, 2024 | Net loss per share | FY2024 | -$1.10 – -$0.80 | New |
| Feb 20, 2024 | Free Cash Flow | FY2024 | $210.00M – $240.00M | New |
| Feb 20, 2024 | U.S. Integrated Care Members | Q1 FY2024 | 89.5 – 90.5 | New |
| Feb 20, 2024 | Integrated Care Adjusted EBITDA margin | Q1 FY2024 | 10.5% – 12% | New |
| Feb 20, 2024 | BetterHelp Adjusted EBITDA margin | Q1 FY2024 | 5.5% – 6.5% | Lowered |
| Feb 20, 2024 | U.S. Integrated Care Members | FY2024 | 90 – 92 | New |
| Feb 20, 2024 | Integrated Care Revenue growth percentage (year-over-year) | Q1 FY2024 | +5% – +7% | New |
| Feb 20, 2024 | BetterHelp Revenue growth percentage (year-over-year) | Q1 FY2024 | -6% – -3% | Lowered |
| Feb 20, 2024 | Revenue | Q1 FY2024 | $630.00M – $645.00M | New |
| Feb 20, 2024 | Revenue | FY2024 | $2.64B – $2.74B | New |
| Oct 24, 2023 | Adjusted EBITDA | Q4 FY2023 | $107.00M – $117.00M | New |
| Oct 24, 2023 | Adjusted EBITDA | FY2023 | $320.00M – $330.00M | Raised |
| Oct 24, 2023 | Net loss per share | Q4 FY2023 | -$0.33 – -$0.23 | New |
| Oct 24, 2023 | Net loss per share | FY2023 | -$1.50 – -$1.40 | Narrowed |
| Oct 24, 2023 | U.S. Integrated Care Members | Q4 FY2023 | 89 – 90 | New |
| Oct 24, 2023 | U.S. Integrated Care Members | FY2023 | 89 – 90 | Raised |
| Oct 24, 2023 | Revenue | Q4 FY2023 | $658.00M – $683.00M | New |
| Oct 24, 2023 | Revenue | FY2023 | $2.60B – $2.63B | Lowered |
| Jul 25, 2023 | Adjusted EBITDA | Q3 FY2023 | $72.00M – $82.00M | New |
| Jul 25, 2023 | Adjusted EBITDA | FY2023 | $300.00M – $325.00M | Raised |
| Jul 25, 2023 | Net loss per share | Q3 FY2023 | -$0.50 – -$0.40 | New |
| Jul 25, 2023 | Net loss per share | FY2023 | -$1.60 – -$1.25 | Raised |
| Jul 25, 2023 | U.S. Integrated Care Members | Q3 FY2023 | 86 | New |
| Jul 25, 2023 | U.S. Integrated Care Members | FY2023 | 86 | Raised |
| Jul 25, 2023 | Revenue | Q3 FY2023 | $650.00M – $675.00M | New |
| Jul 25, 2023 | Revenue | FY2023 | $2.60B – $2.68B | Raised |
| Apr 26, 2023 | Adjusted EBITDA | Q2 FY2023 | $60.00M – $68.00M | New |
| Apr 26, 2023 | Adjusted EBITDA | FY2023 | $285.00M – $325.00M | Raised |
| Apr 26, 2023 | Net loss per share | FY2023 | -$1.70 – -$1.25 | Raised |
| Apr 26, 2023 | Net loss per share | Q2 FY2023 | -$0.55 – -$0.45 | New |
| Apr 26, 2023 | U.S. Integrated Care Members | FY2023 | 84 – 86 | Reaffirmed |
| Apr 26, 2023 | U.S. Integrated Care Members | Q2 FY2023 | 84.5 – 85.5 | New |
| Apr 26, 2023 | Revenue | Q2 FY2023 | $635.00M – $660.00M | New |
| Apr 26, 2023 | Revenue | FY2023 | $2.58B – $2.68B | Raised |
| Feb 22, 2023 | Adjusted EBITDA | Q1 FY2023 | $42.00M – $50.00M | New |
| Feb 22, 2023 | Adjusted EBITDA | FY2023 | $275.00M – $325.00M | New |
| Feb 22, 2023 | Net loss per share | Q1 FY2023 | -$0.55 – -$0.45 | New |
| Feb 22, 2023 | Net loss per share | FY2023 | -$1.75 – -$1.25 | New |
| Feb 22, 2023 | U.S. Integrated Care Members | Q1 FY2023 | 84 – 85 | New |
| Feb 22, 2023 | U.S. Integrated Care Members | FY2023 | 84 – 86 | New |
| Feb 22, 2023 | Revenue | Q1 FY2023 | $610.00M – $625.00M | New |
| Feb 22, 2023 | Revenue | FY2023 | $2.55B – $2.68B | New |
| Oct 26, 2022 | EBITDA | Q4 FY2022 | $10.00M – $37.00M | New |
| Oct 26, 2022 | Adjusted EBITDA | Q4 FY2022 | $88.00M – $98.00M | Raised |
| Oct 26, 2022 | EBITDA | FY2022 | -$17.00M – $10.00M | Lowered |
| Oct 26, 2022 | Adjusted EBITDA | FY2022 | $240.00M – $250.00M | Raised |
| Oct 26, 2022 | Net loss per share | Q4 FY2022 | -$0.40 – -$0.10 | New |
| Oct 26, 2022 | Net loss per share | FY2022 | -$61.40 – -$61.10 | Narrowed |
| Oct 26, 2022 | Visit Fee Only Access | Q4 FY2022 | 24 | Lowered |
| Oct 26, 2022 | Total U.S. Paid Membership | Q4 FY2022 | 57 – 58 | New |
| Oct 26, 2022 | Total Visits | Q4 FY2022 | 4.7 – 4.9 | Lowered |
| Oct 26, 2022 | Total U.S. Paid Membership | FY2022 | 57 – 58 | Raised |
| Oct 26, 2022 | Visit Fee Only Access | FY2022 | 24 | Lowered |
| Oct 26, 2022 | Total Visits | FY2022 | 18.4 – 18.6 | Lowered |
| Oct 26, 2022 | Revenue | FY2022 | $2.40B – $2.41B | Lowered |
| Oct 26, 2022 | Revenue | Q4 FY2022 | $625.00M – $640.00M | New |
| Jul 27, 2022 | EBITDA | Q3 FY2022 | -$46.00M – -$29.00M | New |
| Jul 27, 2022 | Adjusted EBITDA | Q3 FY2022 | $35.00M – $45.00M | Raised |
| Jul 27, 2022 | EBITDA | FY2022 | -$41.00M – $8.00M | Lowered |
| Jul 27, 2022 | Adjusted EBITDA | FY2022 | $240.00M – $265.00M | Raised |
| Jul 27, 2022 | Net loss per share | Q3 FY2022 | -$0.85 – -$0.60 | New |
| Jul 27, 2022 | Net loss per share | FY2022 | -$62.00 – -$61.00 | Lowered |
| Jul 27, 2022 | Total U.S. Paid Membership | Q3 FY2022 | 55.5 – 56.5 | New |
| Jul 27, 2022 | Visit Fee Only Access | Q3 FY2022 | 24 | Lowered |
| Jul 27, 2022 | Total Visits | Q3 FY2022 | 4.8 – 5 | Lowered |
| Jul 27, 2022 | Total U.S. Paid Membership | FY2022 | 55 – 56.5 | Raised |
| Jul 27, 2022 | Visit Fee Only Access | FY2022 | 24 | Lowered |
| Jul 27, 2022 | Total Visits | FY2022 | 18.8 – 19.3 | Lowered |
| Jul 27, 2022 | Revenue | Q3 FY2022 | $600.00M – $620.00M | New |
| Jul 27, 2022 | Revenue | FY2022 | $2.40B – $2.50B | Reaffirmed |
| Apr 27, 2022 | EBITDA | FY2022 | -$52.00M – -$7.00M | Lowered |
| Apr 27, 2022 | EBITDA | Q2 FY2022 | -$37.00M – -$22.00M | New |
| Apr 27, 2022 | Adjusted EBITDA | FY2022 | $240.00M – $265.00M | Raised |
| Apr 27, 2022 | Adjusted EBITDA | Q2 FY2022 | $39.00M – $49.00M | Raised |
| Apr 27, 2022 | Net loss per share | FY2022 | -$43.50 – -$43.00 | Lowered |
| Apr 27, 2022 | Net loss per share | Q2 FY2022 | -$0.72 – -$0.60 | New |
| Apr 27, 2022 | Visit Fee Only Access | Q2 FY2022 | 25 | Lowered |
| Apr 27, 2022 | Total U.S. Paid Membership | Q2 FY2022 | 54 – 55 | New |
| Apr 27, 2022 | Total Visits | Q2 FY2022 | 4.4 – 4.6 | Lowered |
| Apr 27, 2022 | Total U.S. Paid Membership | FY2022 | 54 – 56 | Raised |
| Apr 27, 2022 | Visit Fee Only Access | FY2022 | 25 | Lowered |
| Apr 27, 2022 | Total Visits | FY2022 | 18.5 – 19.5 | Lowered |
| Apr 27, 2022 | Revenue | FY2022 | $2.40B – $2.50B | Lowered |
| Apr 27, 2022 | Revenue | Q2 FY2022 | $580.00M – $600.00M | New |
| Feb 22, 2022 | EBITDA | Q1 FY2022 | -$23.00M – -$16.00M | New |
| Feb 22, 2022 | Adjusted EBITDA | Q1 FY2022 | $51.00M – $55.00M | Raised |
| Feb 22, 2022 | EBITDA | FY2022 | $18.00M – $48.00M | New |
| Feb 22, 2022 | Adjusted EBITDA | FY2022 | $330.00M – $355.00M | Raised |
| Feb 22, 2022 | Net loss per share | Q1 FY2022 | -$0.60 – -$0.50 | New |
| Feb 22, 2022 | Net loss per share | FY2022 | -$1.60 – -$1.40 | New |
| Feb 22, 2022 | Total Visits | Q1 FY2022 | 4.3 – 4.5 | Lowered |
| Feb 22, 2022 | Total U.S. Paid Membership | Q1 FY2022 | 54 – 54.5 | New |
| Feb 22, 2022 | Visit Fee Only Access | Q1 FY2022 | 24 – 25 | Lowered |
| Feb 22, 2022 | Total U.S. Paid Membership | FY2022 | 54 – 56 | New |
| Feb 22, 2022 | Visit Fee Only Access | FY2022 | 24 – 25 | Lowered |
| Feb 22, 2022 | Total Visits | FY2022 | 18.5 – 20 | Lowered |
| Feb 22, 2022 | Revenue | FY2022 | $2.55B – $2.65B | New |
| Feb 22, 2022 | Revenue | Q1 FY2022 | $565.00M – $571.00M | New |
| Oct 27, 2021 | EBITDA | Q4 FY2021 | -$8.00M – -$3.00M | New |
| Oct 27, 2021 | Adjusted EBITDA | Q4 FY2021 | $69.00M – $74.00M | Raised |
| Oct 27, 2021 | EBITDA | FY2021 | -$80.00M – -$75.00M | New |
| Oct 27, 2021 | Adjusted EBITDA | FY2021 | $260.00M – $265.00M | Raised |
| Oct 27, 2021 | Net loss per share | Q4 FY2021 | -$0.73 – -$0.53 | New |
| Oct 27, 2021 | Net loss per share | FY2021 | -$3.40 – -$3.20 | New |
| Oct 27, 2021 | Total U.S. paid membership | Q4 FY2021 | 52.5 – 53.5 | New |
| Oct 27, 2021 | visit fee only access | Q4 FY2021 | 23 – 24 | Lowered |
| Oct 27, 2021 | Total visits | Q4 FY2021 | 3.9 – 4.1 | Lowered |
| Oct 27, 2021 | Total U.S. paid membership | FY2021 | 52.5 – 53.5 | New |
| Oct 27, 2021 | visit fee only access | FY2021 | 23 – 24 | Lowered |
| Oct 27, 2021 | Total visits | FY2021 | 14.5 – 14.7 | Lowered |
| Oct 27, 2021 | Total revenue | Q4 FY2021 | $536.00M – $546.00M | New |
| Oct 27, 2021 | Total revenue | FY2021 | $2.02B – $2.03B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Teladoc Health filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Results
- Update
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?